Copyright
©The Author(s) 2021.
World J Gastroenterol. Oct 21, 2021; 27(39): 6647-6658
Published online Oct 21, 2021. doi: 10.3748/wjg.v27.i39.6647
Published online Oct 21, 2021. doi: 10.3748/wjg.v27.i39.6647
Overall (n = 126) | CD (n = 57) | UC (n = 69) | P value | |
Age (mean ± SD) | 46.13 (± 16.95) | 42.29 (± 15.7) | 49.29 (± 17.38) | 0.03 |
Male | 71 (56.4%) | 33 (57.9%) | 38 (55.1%) | 0.86 |
BMI | 23.9 (± 4.1) | 23.9 (± 4.3) | 23.9 (± 3.9) | 0.67 |
Disease duration (median, IQR) | 8 (3-16) | 10 (3-17) | 8 (3.5-13) | 0.44 |
Disease characteristics (CD) | ||||
Location (CD) | - | - | ||
Terminal ileum (L1) | 13 (22.8%) | |||
Colon (L2) | 8 (14.0%) | |||
Ileo-colon (L3) | 28 (49.1%) | |||
Upper GI (L4) | 2 (3.5%) | |||
Perianal disease (p) | 19 (33.3%) | |||
Behavior (CD) | - | - | ||
Inflammatory (B1) | 32 (56.1%) | |||
Stricturing (B2) | 25 (43.9%) | |||
Penetrating (B3) | 16 (28.1%) | |||
Disease activity (HBI) | - | - | ||
< 5 | 38 (66.7%) | |||
5-7 | 14 (24.6%) | |||
8-16 | 5 (8.8%) | |||
> 16 | - | 0 (0%) | ||
Disease characteristics (UC) | - | |||
Location | - | - | 7 (10.1%) | |
Proctitis (E1) | 26 (37.7%) | |||
Left sided (E2) | 36 (52.2%) | |||
Extensive (E3) | ||||
Disease activity (pMayo) | - | |||
< 2 | 45 (65.2%) | |||
2-4 | 13 (18.8%) | |||
5-7 | 4 (5.8%) | |||
> 7 | 7 (10.1%) | |||
Pouch | 3 (4.4%) | |||
Extraintestinal manifestations | 36 (28.6%) | 17 (29.8%) | 19 (27.5%) | 0.84 |
Previous abdominal surgery | 38 (30.2%) | 22 (38.6%) | 16 (42.1%) | 0.07 |
Calprotectin | 0.54 | |||
< 50 | 43(34.1%) | 15 (26.3%) | 28 (40.6%) | |
51-250 | 33 (16.2%) | 17 (29.8%) | 16 (23.2.%) | |
> 250 | 16 (12.7%) | 7 (12.3%) | 9 (13.4%) | |
Missing | 34 (27.0%) | 18 (31.6%) | 16 (23.2%) | |
CRP | 1.00 | |||
Normal | 77 (61.1) | 35 (62.4%) | 42 (60.9%) | |
Raised | 39 (31.0%) | 18 (31.6%) | 21 (30.4%) | |
Missing | 10 (7.9%) | 4 (7.0%) | 6 (8.7%) | |
Comorbidities | 40 (31.8%) | 16 (28.1%) | 24 (34.8%) | 0.45 |
Cardiomyopathy | 15 (11.9%) | 3 (5.26%) | 12 (17.4%) | 0.05 |
Hypertension | 28 (22.2%) | 12 (42.9%) | 16 (23.2%) | 0.83 |
Diabetes | 11 (8.73%) | 4 (7.0%) | 7 (10.1%) | 0.75 |
Hepatic failure | 1 (0.8%) | 1 (1.8%) | 0 (0.0%) | 0.45 |
Kidney failure | 4 (3.17%) | 3 (5.26%) | 1 (1.45%) | 0.32 |
Respiratory failure | 2 (1.6%) | 1 (1.8%) | 1 (1.5%) | 1.00 |
Neurologic diseases | 5 (4.0%) | 1 (1.8%) | 4 (5.8%) | 0.37 |
Psychiatric disorder | 15 (11.9%) | 7 (12.3%) | 8 (11.6%) | 1.00 |
Onco-hematological diseases | 12 (9.5%) | 2 (3.5%) | 10 (14.5%) | 0.06 |
- Citation: Cococcia S, Lenti MV, Mengoli C, Klersy C, Borrelli de Andreis F, Secco M, Ghorayeb J, Delliponti M, Corazza GR, Di Sabatino A. Validation of the Italian translation of the perceived stigma scale and resilience assessment in inflammatory bowel disease patients. World J Gastroenterol 2021; 27(39): 6647-6658
- URL: https://www.wjgnet.com/1007-9327/full/v27/i39/6647.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i39.6647